SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is surging following reports that the company plans to launch a cloud-computing business to monetize its excess AI computing power. While this has sparked optimism regarding Meta's ability to drive revenue from its massive infrastructure spending, it has triggered volatility in neocloud and semiconductor stocks as investors reassess future supply and competitive dynamics in the AI hardware sector.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending downward following reports that Meta may enter the AI cloud infrastructure market by monetizing its excess compute capacity, sparking investor concerns over potential increased competition and pricing pressure. While the market reaction has been swift, community discussions remain divided between those viewing the news as an overblown fear tactic and others who argue the shift signals a structural threat to the neocloud business model.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and renewed interest as investors pivot toward its expanding pipeline of oncology and rare disease treatments, bolstered by positive FDA briefing documents for its mRNA flu vaccine candidate. The community is actively debating the stock's potential for a short squeeze and long-term re-rating, closely monitoring institutional accumulation and upcoming investor events.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy is currently facing heightened volatility as investors weigh the impact of an accelerated share offering alongside the company's critical role in meeting AI-driven electricity demand. Community sentiment remains largely bullish on the long-term potential of the nuclear fleet to power data centers, with many traders actively viewing the current price dip as an opportunity to average down despite short-term regulatory and supply chain concerns.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending due to significant retail interest in a potential short squeeze, fueled by its low float and high short interest compared to sector peers. The community is actively debating the stock's turnaround potential and comparing it to other high-volatility meme plays, while investors monitor for upward momentum following recent debt refinancing initiatives.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to its Investor Day, where the company announced a significant strategic shift toward data center AI, including supply agreements with Meta and Microsoft. Despite these major hyperscaler partnerships and long-term revenue growth targets, the stock has faced downward pressure due to a broader semiconductor sell-off and market skepticism regarding the timeline for these infrastructure contributions.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC is trending due to reports that its advanced manufacturing capacity remains structurally constrained despite aggressive capital expenditure, fueling sustained AI-driven demand and institutional focus on its pricing power. The community is actively debating the company's long-term dominance in the semiconductor supply chain and assessing how its critical role in advanced node fabrication and packaging influences global AI investment cycles.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending as traders speculate on a potential parabolic breakout similar to historical patterns, fueled by a high concentration of insider ownership and extremely limited share availability. The community is actively discussing the potential for a massive short squeeze while debating the stock's fundamental volatility and its history as a high-stakes meme runner.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is driving market conversation following a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move to bolster its oncology pipeline ahead of the looming Keytruda patent cliff. Investors are now actively debating whether this signals a broader M&A frenzy, with community sentiment split between those praising the premium deal and those speculating on which high-potential biotech might be the next buyout target.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing significant volatility as investors react to reports of Meta potentially monetizing its own excess AI compute capacity, which has sparked concerns about long-term competitive pressure on neocloud providers. Despite the sell-off, community discussion remains divided, with many market participants viewing the move as a narrative-driven overreaction and pointing to robust, multi-year demand and existing contractual backlogs as evidence that the core AI infrastructure thesis remains intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday

Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com...

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Still a Buy?

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Should You Buy...

Research Analysts Set Expectations for ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus...

Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-acrivon-therapeutics-inc-stock...

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer

Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,024,627...

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Acrivon Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACRVACRIVON THERAPEUTICS INC

Fundamentals

Latest ACRV News